Summary
Gilead Sciences, Inc. (GILD) demonstrated robust financial performance for the nine months ended September 30, 2008, with total revenues reaching $3.91 billion, a significant increase from $3.14 billion in the prior year period. This growth was primarily driven by strong product sales, particularly in the antiviral segment, which rose 36% year-over-year to $3.40 billion. Truvada and Atripla were key contributors, showing substantial sales increases. Net income for the nine months also saw healthy growth, climbing to $1.44 billion from $1.21 billion in the same period last year. The company's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $3.26 billion as of September 30, 2008. Gilead continues to actively manage its capital through share repurchases, notably an accelerated share repurchase program initiated in October 2008. Research and development expenses increased, reflecting ongoing investment in pipeline development. Despite a decrease in royalty revenues, primarily due to lower Tamiflu sales, the company's core product sales growth indicates a positive operational trajectory.
Financial Highlights
28 data points| Revenue | $1.37B |
| Cost of Revenue | $300.18M |
| Gross Profit | $1.07B |
| SG&A Expenses | $189.19M |
| Operating Expenses | $677.43M |
| Operating Income | $693.83M |
| Interest Expense | $16.38M |
| Net Income | $495.85M |
| EPS (Basic) | $0.27 |
| EPS (Diluted) | $0.26 |
| Shares Outstanding (Basic) | 1.84B |
| Shares Outstanding (Diluted) | 1.92B |
Key Highlights
- 1Total revenues increased by 24.6% year-over-year for the nine months ended September 30, 2008, reaching $3.91 billion.
- 2Product sales grew by 37% year-over-year for the nine months ended September 30, 2008, totaling $3.70 billion, driven by strong performance in antiviral products.
- 3Net income for the nine months ended September 30, 2008, increased to $1.44 billion, up from $1.21 billion in the prior year period.
- 4The company's cash, cash equivalents, and marketable securities position strengthened, reaching $3.26 billion as of September 30, 2008.
- 5Research and development expenses increased by 28% year-over-year for the nine months, indicating continued investment in pipeline development.
- 6Royalty revenues decreased significantly by 55% year-over-year for the nine months, largely due to reduced Tamiflu sales by Roche.
- 7Gilead continued its share repurchase program, including a $750 million accelerated share repurchase in October 2008.